Neoadjuvant Chemotherapy May Help Some Breast Cancer Patients Skip Regional Nodal Irradiation
Treatment de-escalation may be an option for patients whose lymph nodes become cancer free after neoadjuvant treatment SAN ANTONIO...
Search/Filter
Loading...
Tucatinib Plus Trastuzumab Emtansine May Benefit Patients With Advanced or Metastatic HER2-positive Breast Cancer
SAN ANTONIO – A combination of two HER2-targeted drugs, tucatinib (Tukysa) and trastuzumab emtansine (Kadcyla, T-DM1), extended progression-free survival...
Award Recipients Announced for the 2023 San Antonio Breast Cancer Symposium
SAN ANTONIO – The San Antonio Breast Cancer Symposium (SABCS) and the American Association for Cancer Research (AACR), an...
AACR Applauds Presidential Appointment of W. Kimryn Rathmell, MD, PhD, as Director of the National Cancer Institute
AACR expresses appreciation to Monica Bertagnolli, MD, for her stewardship of NCI before becoming NIH director in early November PHILADELPHIA...
AACR and St. Baldrick’s Foundation Announce Pediatric Cancer Research Grant Recipient
PHILADELPHIA – The American Association for Cancer Research (AACR) and the St. Baldrick’s Foundation today announced that Alanna Joyce...
More Than 10% of Samples From a Stool-based Colorectal Cancer Test May Be Unsatisfactory
Fewer than half of patients with unsatisfactory samples from fecal immunochemical tests completed follow-up testing within 15 months PHILADELPHIA...
AACR Applauds Confirmation of Dr. Monica Bertagnolli as NIH Director
PHILADELPHIA – Philip D. Greenberg, MD, FAACR, President of the American Association for Cancer Research (AACR), and Margaret Foti,...
Nearly Half of Oncology Drugs Approved Since 1998 Are Precision Therapies
Cancer patients eligible for precision oncology therapies nearly doubled between 2017 and 2022 PHILADELPHIA – Of the 198 new...
Investigational Inhibitor of Active RAS Shows Clinical Promise
The therapy uses a different mechanism than approved KRAS G12C inhibitors and targets multiple RAS mutations beyond KRAS G12C...
New Investigational Targeted Therapy Shows Early Promise in Patients With Solid Tumors
Second-generation PRMT5 inhibitor targets synthetic lethality in several cancer types with MTAP loss BOSTON – AMG 193, a second-generation...